Latest News

Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.

New research covers a 3D OCT foundation model, an OCTA biomarker review and offline smartphone screening for three retinal diseases.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Study authors discuss fishing-related eye injury patterns, pediatric risk, and prevention strategies drawn from other sports.

A gamified program may speed the brain’s adjustment, new data suggest.

Giant cell arteritis, long known by its more familiar name, temporal arteritis, is the most common vasculitis in adults over 50 and a true ophthalmic emergency. If untreated, it can result in permanent bilateral vision loss within days. Women are more often afffected than men, the the disease manifests differently between the sexes.

Zero Blind Babies uses wide-field retinal imaging and telemedicine to expand ROP screening across Ghana, Ethiopia, Tanzania, and Syria—screening 400 infants weekly at $56 per QALY—while stressing that local staff and complete-pathway systems remain essential.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

Jay Chhablani, MD, on how MacTel eyes turn neovascular, when to refer, and what Encelto means for treatment.

A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5°

Survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.

Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.